Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/19/2024 | Q3 2024 | -$0.09 | $0 | |||
08/14/2024 | Q2 2024 | -$0.15 | $0 | |||
03/29/2024 | Q1 2024 | -$0.16 | $0 | |||
12/29/2023 | Q4 2023 | -$0.05 | $0 | |||
09/28/2023 | Q3 2023 | -$0.05 | $0 | |||
06/28/2023 | Q2 2023 | -$0.21 | $0 | |||
03/30/2023 | Q1 2023 | -$0.07 | $0 | |||
12/29/2022 | Q4 2022 | -$0.04 | $0 | |||
09/28/2022 | Q3 2022 | $0.00 | $0 | |||
06/28/2022 | Q2 2022 | -$0.00 | $0 | |||
03/29/2022 | Q1 2022 | -$0.02 | $0 | |||
12/29/2021 | Q4 2021 | -$0.01 | $0 | |||
06/30/2021 | Q2 2021 | -$0.00 | $0 |
CERo Therapeutics Holdings, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates.
The conference call for CERo Therapeutics Holdings, Inc.'s latest earnings report can be listened to online.
The conference call transcript for CERo Therapeutics Holdings, Inc.'s latest earnings report can be read online.
CERo Therapeutics Holdings, Inc. (:CERO) has a recorded net income of $0. CERo Therapeutics Holdings, Inc. has generated $-0.39 earnings per share over the last four quarters.
CERo Therapeutics Holdings, Inc. (:CERO) has a price-to-earnings ratio of -0.32 and price/earnings-to-growth ratio is 0.04.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED